- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01746979
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO)
October 26, 2017 updated by: Threshold Pharmaceuticals
A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
This Phase 3 trial is a randomized, double-blind, placebo-controlled trial of gemcitabine in combination with TH-302 compared to gemcitabine in combination with placebo in subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Randomized subjects will receive TH-302 plus gemcitabine or gemcitabine plus placebo in 4-week cycles until there is evidence of progressive disease, intolerable toxicity, or the subject discontinues from the trial for other reasons (for example, withdrawal of consent).
The primary efficacy endpoint is overall survival (OS) time.
The data cut-off for statistical analyses of the primary and secondary endpoints will be reached when 508 events (deaths) will be reported.
No planned interim analyses will be conducted.
An Independent Safety Monitoring Board (ISMB) will provide periodic evaluations of the unblinded safety data to ensure subject safety and the validity and scientific merit of the study.
A total of 660 subjects will be enrolled.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
693
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Darmstadt, Germany
- Please Contact Merck Communication Center
-
-
-
-
Massachusetts
-
Rockland, Massachusetts, United States
- Please Contact U.S. Medical Information
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least 18 years of age
Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma proven by histology or cytology and previously untreated with chemotherapy or systemic therapy other than:
- Radiosensitizing doses of 5-fluorouracil;
- Radiosensitizing doses of gemcitabine if relapse occurred at least 6 months after completion of gemcitabine;
- Neoadjuvant chemotherapy if relapse occurred at least 6 months after surgical resection;
- Adjuvant chemotherapy if relapse occurred at least 6 months after completion of adjuvant chemotherapy
- Measurable disease (at least one target lesion outside of previous radiation fields) or non-measurable disease by RECIST v.1.1 criteria
- Documentation of disease progression since any prior therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy of at least 3 month
- Acceptable liver, renal function and acceptable hematological status
- Other protocol defined inclusion criteria may apply
Exclusion Criteria:
- New York Heart Association (NYHA) Class III or IV congestive heart failure, myocardial infarction within 6 months prior to the date of randomization, unstable arrhythmia or symptomatic peripheral arterial vascular disease
- Symptomatic ischemic heart disease
- Known brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 3 months)
- Previous malignancy other than pancreatic cancer in the last 5 years, except for adequately treated non-melanoma skin cancer or pre-invasive cancer of the cervix
- Severe chronic obstructive or other pulmonary disease with hypoxemia
- Major surgery, other than diagnostic surgery, less than or equal to 28 days prior to the date of randomization. Subject must have completely recovered from surgery
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- Treatment of pancreatic cancer with radiation therapy or surgery less than or equal to 28 days prior to the date of randomization
- Prior therapy with a hypoxic cytotoxin
- Subjects who participated in an investigational drug or device trial less than or equal to 28 days prior to Day 1 of the first cycle
- Known infection with Human Immunodeficiency Virus (HIV), or an active infection with Hepatitis B or Hepatitis C
- Subjects who have exhibited allergic reactions to a structural compound similar to TH-302 or the drug product excipients or to gemcitabine or its excipients
- Other protocol defined exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Gemcitabine plus TH-302
|
TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle.
Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle.
Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
|
Placebo Comparator: Gemcitabine plus placebo
|
Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle.
Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle.
Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
|
Overall survival is defined as time from randomization to death or last day known to be alive.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
|
Progression Free Survival is defined as the time from randomization to either first observation of progressive disease or occurrence of death.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Antonio Gualberto, MD, PhD, EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2012
Primary Completion (Actual)
February 1, 2016
Study Completion (Actual)
May 1, 2016
Study Registration Dates
First Submitted
December 7, 2012
First Submitted That Met QC Criteria
December 7, 2012
First Posted (Estimate)
December 11, 2012
Study Record Updates
Last Update Posted (Actual)
December 2, 2017
Last Update Submitted That Met QC Criteria
October 26, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
Other Study ID Numbers
- EMR 200592-001
- 2012-002957-42 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
-
FutureGen Biopharmaceutical (Beijing) Co., LtdRecruitingLocally Advanced Unresectable or Metastatic Gastric Cancer | Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaChina
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States
-
Hangzhou Sumgen Biotech Co., Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsChina
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, China, Spain, Japan, United Kingdom
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, Canada
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Shanghai Xianxiang Medical Technology Co., Ltd.; Simcere ZaimingRecruitingLocally Advanced Unresectable or Metastatic Solid TumorUnited States, China
Clinical Trials on TH-302
-
Threshold PharmaceuticalsCompletedAcute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | High-risk Myelodysplastic Syndrome | Advanced MyelofibrosisUnited States
-
Threshold PharmaceuticalsTerminatedMetastatic MelanomaUnited States, Canada
-
Sarcoma Alliance for Research through CollaborationThreshold PharmaceuticalsNo longer availableSoft Tissue Sarcoma
-
Threshold PharmaceuticalsUnknown
-
Threshold PharmaceuticalsCompletedHypoxia | TumorsUnited States
-
Seoul National University HospitalThreshold PharmaceuticalsCompletedBiliary Tract CancerKorea, Republic of
-
Herbert Hurwitz, MDGlaxoSmithKline; National Comprehensive Cancer Network; Threshold PharmaceuticalsCompleted
-
Merck KGaA, Darmstadt, GermanyThreshold PharmaceuticalsCompleted
-
Threshold PharmaceuticalsCompletedSoft Tissue SarcomaUnited States
-
Threshold PharmaceuticalsUnknownGastrointestinal Stromal Tumors | Advanced Renal Cell Carcinoma | Pancreatic Neuroendocrine TumorsUnited States